Cargando…

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?

INTRODUCTION: Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new‐generation TKI (NG‐TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population? MATERIALS AND METHODS: Patients were identified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Canet, Jim, Cony‐Makhoul, Pascale, Orazio, Sébastien, Cornet, Edouard, Troussard, Xavier, Maynadié, Marc, Étienne, Gabriel, Monnereau, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Researcher
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525157/ https://www.ncbi.nlm.nih.gov/pubmed/34551198 http://dx.doi.org/10.1002/cam4.4186

Ejemplares similares

Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based study
por: Foulon, Stéphanie, et al.
Publicado: (2019)

Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role?
por: Le Guyader-Peyrou, Sandra, et al.
Publicado: (2017)

A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
por: Zulbaran‐Rojas, Alejandro, et al.
Publicado: (2018)

P938: SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN THE GENERAL POPULATION BASED ON DATA FROM TWO FRENCH CANCER REGISTRIES
por: Hulin, Cyrille, et al.
Publicado: (2023)

PB1855: USE OF MACHINE LEARNING MODEL TO IDENTIFY PATIENTS RECEIVING OPTIMAL TREATMENT AND THE ASSOCIATED NON-BIOLOGICAL FACTORS: A POPULATION-BASED STUDY
por: Atsou, Kueshivi Midodji, et al.
Publicado: (2023)

Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population‐based study in France
por: Atsou, Kueshivi Midodji, et al.
Publicado: (2023)

Hairy cell leukemia 2018: Update on diagnosis, risk‐stratification, and treatment
por: Troussard, Xavier, et al.
Publicado: (2017)

Hairy cell leukemia: a specific 17-gene expression signature points to new targets for therapy
por: Maitre, Elsa, et al.
Publicado: (2022)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells
por: Glodkowska-Mrowka, E, et al.
Publicado: (2016)

How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)
por: Breccia, Massimo, et al.
Publicado: (2020)

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
por: Casado, Luis-Felipe, et al.
Publicado: (2015)

Polyclonal B-cell lymphocytosis with binucleated lymphocytes (PPBL)
por: Troussard, Xavier, et al.
Publicado: (2008)

Persistent polyclonal binucleated B-cell lymphocytosis and MECOM gene amplification
por: Cornet, Edouard, et al.
Publicado: (2016)

Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials
por: Vener, Claudia, et al.
Publicado: (2022)

Variant form of hairy cell leukemia
por: Wiber, Margaux, et al.
Publicado: (2019)

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia
por: Lebecque, Benjamin, et al.
Publicado: (2022)

Identification of survival-related alternative splicing signatures in acute myeloid leukemia
por: Zhang, Biyu, et al.
Publicado: (2021)

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study
por: Rousselot, Philippe, et al.
Publicado: (2016)

Targeting β-catenin in acute myeloid leukaemia: past, present, and future perspectives
por: Wagstaff, Megan, et al.
Publicado: (2022)

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34(+) CD15(−) cells in early chronic‐phase chronic myeloid leukemia
por: Maupetit‐Mehouas, Stéphanie, et al.
Publicado: (2018)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
por: Sinha, Meenal, et al.
Publicado: (2023)

Novel analytical methods to interpret large sequencing data from small sample sizes
por: Lichou, Florence, et al.
Publicado: (2019)

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34(−) and immature CD34(+) cells
por: Berger, Marc G., et al.
Publicado: (2021)

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
por: Dulucq, Stephanie, et al.
Publicado: (2022)

BCR‐ABL1 transcript levels at 4 weeks have prognostic significance for time‐specific responses and for predicting survival in chronic‐phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
por: Song, Hye‐young, et al.
Publicado: (2018)

Performance evaluation and relevance of the CellaVision™ DM96 system in routine analysis and in patients with malignant hematological diseases
por: CORNET, E, et al.
Publicado: (2008)

Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
por: Zheng, Guoqiao, et al.
Publicado: (2021)

Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway
por: Chen, Yanli, et al.
Publicado: (2022)

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
por: Dumas, Pierre‐Yves, et al.
Publicado: (2019)

Developing Molecular Signatures for Chronic Lymphocytic Leukemia
por: Cornet, Edouard, et al.
Publicado: (2015)

Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders
por: Maitre, Elsa, et al.
Publicado: (2022)

Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy
por: Rodriguez, Jonathan, et al.
Publicado: (2023)

Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients
por: Chen, Chang-Zhi, et al.
Publicado: (2021)

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study
por: Haguet, Hélène, et al.
Publicado: (2020)

Tumour stage and gender predict recurrence and second primary malignancies in head and neck cancer: a multicentre study within the INHANCE consortium
por: Leoncini, Emanuele, et al.
Publicado: (2018)

Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model
por: Taurin, Sebastien, et al.
Publicado: (2018)

Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors
por: García-Gutiérrez, Valentín, et al.
Publicado: (2020)

Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
por: Hochhaus, Andreas, et al.
Publicado: (2020)

High number of PD‐1 positive intratumoural lymphocytes predicts survival benefit of cytokine‐induced killer cells for hepatocellular carcinoma patients
por: Chang, Boyang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4c8r1ajpgikfvchb5rdcsrm10k